Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Medicure (MCUJF) Liabilities and Shareholders Equity (2016 - 2025)

Medicure has reported Liabilities and Shareholders Equity over the past 17 years, most recently at $17.9 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 15.79% year-over-year to $17.9 million; the TTM value through Dec 2025 reached $78.6 million, down 6.53%, while the annual FY2025 figure was $17.9 million, 15.79% down from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $17.9 million at Medicure, down from $19.4 million in the prior quarter.
  • Over five years, Liabilities and Shareholders Equity peaked at $25.2 million in Q2 2021 and troughed at $17.9 million in Q4 2025.
  • A 5-year average of $21.8 million and a median of $21.5 million in 2023 define the central range for Liabilities and Shareholders Equity.
  • Biggest five-year swings in Liabilities and Shareholders Equity: dropped 22.4% in 2021 and later increased 3.08% in 2024.
  • Year by year, Liabilities and Shareholders Equity stood at $22.5 million in 2021, then decreased by 2.27% to $22.0 million in 2022, then decreased by 6.43% to $20.6 million in 2023, then rose by 3.08% to $21.2 million in 2024, then dropped by 15.79% to $17.9 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for MCUJF at $17.9 million in Q4 2025, $19.4 million in Q3 2025, and $20.5 million in Q2 2025.